Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells 23,125 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 23,125 shares of the business’s stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the sale, the chief executive officer now directly owns 307,972 shares in the company, valued at approximately $14,182,110.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, September 11th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.50, for a total value of $585,937.50.
• On Wednesday, August 21st, Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock. The stock was sold at an average price of $39.76, for a total value of $575,366.96.

Vera Therapeutics Trading Down 4.9 %

Shares of VERA traded down $2.22 during trading hours on Friday, hitting $43.44. 691,934 shares of the stock were exchanged, compared to its average volume of 912,647. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43. The firm has a market capitalization of $2.38 billion, a P/E ratio of -22.27 and a beta of 0.99. The business has a 50-day moving average of $38.23 and a 200-day moving average of $39.11. Vera Therapeutics, Inc. has a fifty-two week low of $9.24 and a fifty-two week high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). On average, research analysts expect that Vera Therapeutics, Inc. will post -2.57 EPS for the current year.

Wall Street Analyst Weigh In

VERA has been the subject of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research note on Monday. JPMorgan Chase & Co. upped their price target on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Finally, Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $51.75.

Hedge Funds Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VERA. Ameritas Investment Partners Inc. increased its stake in shares of Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after acquiring an additional 688 shares in the last quarter. Arizona State Retirement System grew its holdings in Vera Therapeutics by 14.4% in the second quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock worth $358,000 after purchasing an additional 1,250 shares during the period. Ensign Peak Advisors Inc increased its stake in Vera Therapeutics by 13.5% in the second quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock valued at $425,000 after purchasing an additional 1,400 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Vera Therapeutics by 30.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock valued at $272,000 after purchasing an additional 1,737 shares during the period. Finally, American International Group Inc. raised its holdings in shares of Vera Therapeutics by 17.6% during the first quarter. American International Group Inc. now owns 19,764 shares of the company’s stock valued at $852,000 after purchasing an additional 2,957 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.